Patient Identification
Which Patients May Benefit from Protected PCI?
The FDA has determined Impella CP® with SmartAssist® to be safe and effective for hemodynamic support in elective and urgent high-risk PCI. When surgery is not an option, Impella® may provide a viable alternative, helping optimize outcomes for patients with complex coronary artery disease, hemodynamic compromise and comorbidities.
Patients benefit from this minimally invasive option that may:
- Enable more complete revascularization1
- Reduce symptoms and class of heart failure2 and improve LVEF1
- Significantly reduce the overall incidence of post-procedural acute kidney injury (AKI)5
- Reduce number of days in the hospital3,4
- Significantly reduce post-discharge MACCE events (composite of death/stroke/MI/repeat revascularization)6
Surgical Turndown is Common and Associated with Higher Mortality
Protected PCI may be an option when surgery is not. Consider Protected PCI for patients who are considered too high-risk and therefore turned down for surgery, and for patients who decline surgical treatment.
Underdiagnosed & Undertreated
Many patients with severe, symptomatic CAD remain untreated or undertreated due to comorbidities, increased risk of AKI or hemodynamic compromise.
Resources
References
1.) Burzotta, L., et al. (2019). Title of the article. Journal of Interventional Cardiology, 2019(5), 1-10.
2.) O'Neill, W. C., et al. (2012). Title of the article. Circulation, 126(14), 1717-1727.
3.) Gregory, D., et al. (2013). Title of the article. American Health & Drug Benefits, 6(2), 88-99.
4.) Maini, B., et al. (2014). Title of the article. Expert Review of Pharmacoeconomics & Outcomes Research, 14(3), 403-416.
5.) Flaherty, M. P., et al. (2017). Title of the article. Circulation Research, 120(4), 692-700.
6.) Dangas, G. D., et al. (2014). Title of the article. American Journal of Cardiology, 113(2), 222-228.
NPS-1180